Miscellaneous Dermatological Conditions

FDA Fast-Tracks Treatment for Pachyonychia Congenita

By November 13, 2018

Through Palvella's proprietary QTORIN formulation, PTX-022 targets basal keratinocytes, which harbor the mutant keratin genes that cause PC.

Dermatologic Adverse Events Common With Targeted Therapies, Immunotherapies

By November 06, 2018

"Closer collaboration between dermatologists and oncologists is essential," write the authors.

Dupilumab Gets Priority Review for Adolescent Atopic Dermatitis

By November 06, 2018

Dupixent is also being assessed in other allergic/inflammatory conditions, including pediatric atopic dermatitis, pediatric asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, grass allergy, and peanut allergy.

Nuzyra Approved for CABP, Acute Skin/Skin Structure Infections

By October 03, 2018

The approval was based on Phase 3 data from 2 studies in ABSSSI, where treatment with Nuzyra was compared with linezolid, and 1 study in CABP comparing Nuzyra with moxifloxacin. Across all 3 trials, Nuzyra was found to be effective and generally safe and well-tolerated.

Qbrexza Now Available for the Treatment of Primary Axillary Hyperhidrosis

By October 01, 2018

A single cloth should be used to apply Qbrexza to both underarms.

First Treatment for Advanced Cutaneous Squamous Cell Carcinoma FDA-Approved

By October 01, 2018

The approval was based on data from 2 open-label studies where patients with metastatic CSCC or locally advanced CSCC who were not candidates for curative surgery or curative radiation received Libtayo 3mg/kg intravenously every 2 weeks for up to 48 weeks or up to 96 weeks until disease progression, unacceptable toxicity, or completion of planned treatment.

Patient Develops Rare Extrapulmonary Manifestation of Tuberculosis

By September 21, 2018

The patient, a 42-year-old female with systemic lupus erythematosus treated with mycophenolate mofetil and prednisone, reported swelling and pain in the fifth finger of her left hand for about 1-week.

RECELL System Approved to Treat Severe Burns

By September 21, 2018

At Week 8 post-treatment, 92% of the burn sites treated with RECELL System achieved complete healing vs 85% of sites treated with standard-of-care, demonstrating non-inferiority.

Contezolid Gets QIDP, Fast Track Status for Acute Bacterial Skin/Skin Structure Infections

By September 21, 2018

The structure of contezolid was designed to potentially reduce the risk of hematological toxicity associated with this class of antibiotics.

Dupilumab Beneficial in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis

By September 18, 2018

The Phase 3 trial enrolled 251 patients aged 12-17 years old with moderate-to-severe atopic dermatitis, whose disease was not adequately controlled by prescription topical medications or for whom topical treatment was medically inadvisable.

Novel Treatment for Pemphigus Granted Orphan Drug Designation

By September 13, 2018

Preliminary results from a Phase 1b proof-of-concept study showed that SYNT001 was associated with clinical improvement (as measured by Pemphigus Disease Area Index score) and induced a rapid reduction in lgG and circulating immune complex levels.

Patient's Black Hairy Tongue Linked to Antibiotic Therapy

By September 10, 2018

The case involved a 55-year-old female patient who had been admitted to the hospital after suffering injuries from a car accident.

Oral JAK3 Inhibitor Granted Breakthrough Tx Designation for Alopecia Areata

By September 05, 2018

PF-06651600 is an investigational oral Janus kinase 3 (JAK3) inhibitor that is being evaluated in a Phase 2 study which will assess the treatment based on changes from baseline in Severity of Alopecia Tool (SALT) score.

Gene Therapy for Localized Scleroderma Gets FDA's Fast Track Designation

By September 05, 2018

Clinical enrollment for an open-label, single-arm Phase 1/2 trial of FCX-013 was initiated in August 2018.

Iclaprim Gets Priority Review for Acute Bacterial Skin/Skin Structure Infections

By August 15, 2018

Clinical data has indicated that the drug exhibits a low propensity for resistance development as well as a favorable tolerability profile.

Gene Therapy Gets Orphan Drug Designation for Severe Genetic Skin Disease

By August 13, 2018

Patients with TGM-1 deficiency may have chronic pronounced scaling of the skin with increased transepidermal water loss, as the TGM-1 enzyme is essential for facilitating the formation of the epidermal barrier, which prevents dehydration.

Omadacycline Gets FDA Committee Nod for Skin Infections, Pneumonia

By August 09, 2018

The Committee's recommendation was based on data from the omadacycline global development program that included nearly 2000 adults in three Phase 3 studies.

Skin Appears to Be Key Pathway for Absorption of BBQ Fumes

August 06, 2018

"In the case of BBQ fumes, dermal absorption was a more important pathway for intake of low-molecular-weight PAHs than inhalation," the authors write.

Teen Boy Suffers Serious Burns After 'Hot Water Challenge'

July 31, 2018

Clark spent a week in the hospital. His doctors are hopeful that pigment will return in Clark's face within a few months.

Atopic Dermatitis Places Heavy Burden on Patients

July 20, 2018

Adults with AD reported higher proportions of having only fair/poor overall health, being somewhat/very dissatisfied with life, having lower weighted mean Short-Form 12 (SF-12) mental and physical health subscores, and having higher Dermatology Life Quality Index scores, compared to adults without AD.

Fish Pedicure Causes Woman to Lose Toenails

July 16, 2018

Dermatologists should be aware of potential skin, nail problems tied to fish pedicures

Topical JAK Inhibitor Granted Fast Track Designation for Alopecia Areata

By July 09, 2018

ATI-502 is a topical Janus Kinase (JAK) 1/3 inhibitor.

Novel Treatment for Primary Axillary Hyperhidrosis Gets FDA Approval

By June 29, 2018

The approval was supported by Phase 3 data from the ATMOS-1 and ATMOS-2 trials which evaluated the absolute change from baseline in sweat production after treatment with Qbrexza, and the proportion of patients who achieved ≥4-point improvement from baseline in their sweating severity (as measured by the Axillary Sweating Daily Diary [ASDD]).

Treatment for Necrobiosis Lipoidica Gets Orphan Drug Designation

By June 22, 2018

In a press release Dr. David Young, CEO of Processa said "We plan to begin our clinical studies in 2018 and to accelerate the development of PCS499 in order to provide clinical benefit to [necrobiosis lipoidica] patients as soon as possible."

Treatment of Hidradenitis Suppurativa with SAPHO Syndrome: A Case Review

By June 21, 2018

The male patient presented in 2009 with a "3-year history of multiple interconnecting comedones in the axilla and inguinal regions, as well as scarring from previous lesions."

Topical Rapamycin Effective for TSC-Related Facial Angiofibromas

June 11, 2018

The researchers observed clinically meaningful and statistically significant improvement in facial angiofibromas for 1 and 0.1% rapamycin versus vehicle only, and for 1 vs 0.1% rapamycin; most of the improvement was seen in the first month.

Rituxan Approved for Moderate to Severe Pemphigus Vulgaris

By June 08, 2018

The approval was based on data from the Ritux 3 trial (N=90) which compared rituximab + short-term oral prednisone (Ritux 3 regimen) to oral prednisone alone as a first-line treatment for patients with newly diagnosed moderate to severe PV.

Physician Sued for Negligence After Relying on Patient's Self-Diagnosis

By June 04, 2018

This month we look at the issue of whether a physician can be liable for relying on information provided by the patient.

Topically-Applied Gene Tx Fast-Tracked for Dystrophic Epidermolysis Bullosa

By May 25, 2018

KB103 is a replication-defective, non-integrating viral vector that utilizes the Company's STAR-D platform to deliver functional human COL7A1 genes directly to the patients' dividing and non-dividing skin cells.

Research Lacking on Platelet-Rich Tx for Facial Aesthetics, Alopecia

May 25, 2018

The researchers identified 7 studies that used platelet-rich plasma alone for facial rejuvenation, 7 in combination with fat grafting, 2 for treatment of acne scarring, and 6 for treatment of androgenic alopecia.